Landscape of Somatic and Age-Related Pathogenic Structural Variations in Hepatocellular Carcinoma Revealed by Long-Read Sequencing

Abstract

Hepatocellular carcinoma (HCC) was characterized by a highly complex genome, with structural variations (SVs) playing a significant role in its development. In this study, we employed Oxford Nanopore Technology long-read sequencing in paired tumor and adjacent normal liver tissues from 74 Chinese HCC patients to thoroughly characterize the landscape of somatic SVs. Our analysis revealed that somatic SVs were more prevalent in hepatitis B virus (HBV)-related HCC, with chromosome 1 emerging as a major hotspot, and several members of the chromosome 1 open reading frame (C1orf) family genes expression level exhibited significant age-related difference. Notably, HBV-related HCC cases exhibited a higher frequency of deletions, particularly among younger ones (≤ 35 years old). In addition, we observed an increased burden of HBV integration events in younger ones. Remarkably, the divergent-paired related homeobox (DPRX) loci was identified as a novel gene for HBV integration in younger patients. Together, these findings delineated the somatic SV landscape in HCC and underscored age-associated HBV-related genomic alterations as key pathological features of hepatocarcinogenesis.

Keywords

hepatitis B virus integration / hepatocellular carcinoma / long-read sequencing / somatic structural variations / younger ones

References

[1] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209–249.

[2] S. Y. Hwang, P. Danpanichkul, and V. Agopian, “Hepatocellular Carcinoma: Updates on Epidemiology, Surveillance, Diagnosis and Treatment,” Clinical and Molecular Hepatology 31, no. Supp l (2025): S228–S254.

[3] B. Han, R. Zheng, H. Zeng, et al., “Cancer Incidence and Mortality in China, 2022,” Journal of the National Cancer Center 4, no. 1 (2024): 47–53.

[4] J. Lin, H. Zhang, H. Yu, et al., “Epidemiological Characteristics of Primary Liver Cancer in Mainland China From 2003 to 2020: A Representative Multicenter Study,” Frontiers in Oncology 12 (2022): 906778.

[5] Z. Qian, J. Liang, R. Huang, et al., “HBV Integrations Reshaping Genomic Structures Promote Hepatocellular Carcinoma,” Gut 73, no. 7 (2024): 1169–1182.

[6] R. Dhanasekaran, S. Bandoh, and L. R. Roberts, “Molecular Pathogenesis of Hepatocellular Carcinoma and Impact of Therapeutic Advances,” F1000Research 5 (2016).

[7] M. R. Cosenza, B. Rodriguez-Martin, and J. O. Korbel, “Structural Variation in Cancer: Role, Prevalence, and Mechanisms,” Annual Review of Genomics and Human Genetics 23 (2022): 123–152.

[8] J. Zhao and S. Shen, “Discover Novel Biomarkers Using Population-Scale Whole-Genome Sequencing,” Innovation Medicine 3, no. 4 (2025): 100168.

[9] P. A. Audano, A. Sulovari, T. A. Graves-Lindsay, et al., “Characterizing the Major Structural Variant Alleles of the Human Genome,” Cell 176, no. 3 (2019): 663–675. e19.

[10] C. Peneau and S. Imbeaud, “Hepatitis B Virus Integrations Promote Local and Distant Oncogenic Driver Alterations in Hepatocellular Carcinoma,” Gut 71, no. 3 (2022): 616–626.

[11] Y. Totoki, K. Tatsuno, and K. R. Covington, “Trans-Ancestry Mutational Landscape of Hepatocellular Carcinoma Genomes,” Nature Genetics 46, no. 12 (2014): 1267–1273.

[12] K. Schulze, S. Imbeaud, E. Letouze, et al., “Exome Sequencing of Hepatocellular Carcinomas Identifies New Mutational Signatures and Potential Therapeutic Targets,” Nature Genetics 47, no. 5 (2015): 505–511.

[13] A. Fujimoto, M. Furuta, Y. Totoki, et al., “Whole-Genome Mutational Landscape and Characterization of Noncoding and Structural Mutations in Liver Cancer,” Nature Genetics 48, no. 5 (2016): 500–509.

[14] Cancer Genome Atlas Research Network. Electronic Address W B E, Cancer Genome Atlas Research N. "Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma," Cell 2017, 169(7): 1327–1341.e23.

[15] Q. Gao, H. Zhu, L. Dong, et al., “Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma,” Cell 179, no. 2 (2019): 561–577. e22.

[16] S. Romagnoli, N. Bartalucci, and A. M. Vannucchi, “Resolving Complex Structural Variants via Nanopore Sequencing,” Frontiers in Genetics 14 (2023): 1213917.

[17] D. Beyter, H. Ingimundardottir, A. Oddsson, et al., “Long-read Sequencing of 3,622 Icelanders Provides Insight Into the Role of Structural Variants in Human Diseases and Other Traits,” Nature Genetics 53, no. 6 (2021): 779–786.

[18] Z. Wu, Z. Jiang, T. Li, et al., “Structural Variants in the Chinese Population and Their Impact on Phenotypes, Diseases and Population Adaptation,” Nature Communications 12, no. 1 (2021): 6501.

[19] R. Guldager, S. Nordentoft, M. Bruun-Pedersen, et al., “Social Network Trajectory of Young Adults Aged 18–35 Years Diagnosed With a Brain Tumour: A Protocol for a Mixed Methods Study,” BMJ Open 13, no. 12 (2023): e076337.

[20] B. Liu, X. Quan, C. Xu, et al., “Lung Cancer in Young Adults Aged 35 Years or Younger: A Full-Scale Analysis and Review,” Journal of Cancer 10, no. 15 (2019): 3553–3559.

[21] M. Mahmoud, N. Gobet, and D. I. Cruz-Davalos, “Structural Variant Calling: The Long and the Short of It,” Genome Biology 20, no. 1 (2019): 246.

[22] F. J. Sedlazeck, P. Rescheneder, M. Smolka, et al., “Accurate Detection of Complex Structural Variations Using Single-Molecule Sequencing,” Nature Methods 15, no. 6 (2018): 461–468.

[23] J. M. Kidd, T. Graves, and T. L. Newman, “A Human Genome Structural Variation Sequencing Resource Reveals Insights Into Mutational Mechanisms,” Cell 143, no. 5 (2010): 837–847.

[24] L. Yang, L. J. Luquette, N. Gehlenborg, et al., “Diverse Mechanisms of Somatic Structural Variations in Human Cancer Genomes,” Cell 153, no. 4 (2013): 919–929.

[25] J. M. Flynn, R. Hubley, and C. Goubert, “RepeatModeler2 for Automated Genomic Discovery of Transposable Element Families,” PNAS 117, no. 17 (2020): 9451–9457.

[26] E. G. Alvarez, J. Demeulemeester, and P. Otero, “Aberrant Integration of Hepatitis B Virus DNA Promotes Major Restructuring of Human Hepatocellular Carcinoma Genome Architecture,” Nature Communications 12, no. 1 (2021): 6910.

[27] J. W. Jang, H. S. Kim, J. S. Kim, et al., “Distinct Patterns of HBV Integration and TERT Alterations Between in Tumor and Non-Tumor Tissue in Patients With Hepatocellular Carcinoma,” International Journal of Molecular Sciences 22, no. 13 (2021): 7056.

[28] S. Aganezov, S. Goodwin, and R. M. Sherman, “Comprehensive Analysis of Structural Variants in Breast Cancer Genomes Using Single-Molecule Sequencing,” Genome Research 30, no. 9 (2020): 1258–1273.

[29] L. Shen, Y. Jiang, L. Lu, et al., “Dynamic Prognostication and Treatment Planning for Hepatocellular Carcinoma: A Machine Learning-Enhanced Survival Study Using Multi-Centric Data,” Innovation Medicine 3, no. 2 (2025): 100125.

[30] A. Fujimoto, J. H. Wong, Y. Yoshii, et al., “Whole-Genome Sequencing With Long Reads Reveals Complex Structure and Origin of Structural Variation in Human Genetic Variations and Somatic Mutations in Cancer,” Genome Medicine 13, no. 1 (2021): 65.

[31] Y. T. Huang, C. L. Jen, and H. I. Yang, “Lifetime Risk and Sex Difference of Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B and C,” Journal of Clinical Oncology 29, no. 27 (2011): 3643–3650.

[32] F. Liu, Z. Liao, L. Qin, et al., “Targeting VPS72 Inhibits ACTL6A/MYC Axis Activity in HCC Progression,” Hepatology 78, no. 5 (2023): 1384–1401.

[33] C. Sun, W. Xu, Y. Xia, et al., “PRDM16 From Hepatic Stellate Cells-Derived Extracellular Vesicles Promotes Hepatocellular Carcinoma Progression,” American Journal of Cancer Research 13, no. 11 (2023): 5254–5270.

[34] Y. Liu, C. Yang, S. Chen, et al., “Cancer-Derived Exosomal miR-375 Targets DIP2C and Promotes Osteoblastic Metastasis and Prostate Cancer Progression by Regulating the Wnt Signaling Pathway,” Cancer Gene Therapy 30, no. 3 (2023): 437–449.

[35] C. Zhou, W. Zhang, W. Chen, et al., “Integrated Analysis of Copy Number Variations and Gene Expression Profiling in Hepatocellular Carcinoma,” Scientific Reports 7, no. 1 (2017): 10570.

[36] Y. Yu, Z. Wang, Z. Huang, et al., “C1orf61 Promotes Hepatocellular Carcinoma Metastasis and Increases the Therapeutic Response to Sorafenib,” Biochimica et Biophysica Acta (BBA) – Molecular Cell Research 1868, no. 8 (2021): 119048.

[37] Y. Kurlishchuk, A. Cindric Vranesic, M. Jessen, et al., “A Non-Canonical Repressor Function of JUN Restrains YAP Activity and Liver Cancer Growth,” Embo Journal 43, no. 20 (2024): 4578–4603.

[38] A. L. Heeke, M. J. Pishvaian, F. Lynce, et al., “Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types,” JCO Precision Oncology 2018 (2018): PO.17.00286.

[39] C. L. Lin and J. H. Kao, “Development of Hepatocellular Carcinoma in Treated and Untreated Patients With Chronic Hepatitis B Virus Infection,” Clinical and Molecular Hepatology 29, no. 3 (2023): 605–622.

[40] J. W. Jang, J. S. Kim, H. S. Kim, et al., “Persistence of Intrahepatic Hepatitis B Virus DNA Integration in Patients Developing Hepatocellular Carcinoma After Hepatitis B Surface Antigen Seroclearance,” Clinical and Molecular Hepatology 27, no. 1 (2021): 207–218.

[41] D. Zhang, K. Zhang, U. Protzer, et al., “HBV Integration Induces Complex Interactions Between Host and Viral Genomic Functions at the Insertion Site,” Journal of Clinical and Translational Hepatology 9, no. 3 (2021): 399–408.

[42] Y. Yin, E. Morgunova, A. Jolma, et al., “Impact of Cytosine Methylation on DNA Binding Specificities of Human Transcription Factors,” Science 356, no. 6337 (2017): eaaj2239.

[43] M. Bellon and C. Nicot, “Targeting Pim Kinases in Hematological Cancers: Molecular and Clinical Review,” Molecular Cancer 22, no. 1 (2023): 18.

[44] S. Chen, Y. Yang, Y. Yuan, et al., “Targeting PIM Kinases in Cancer Therapy: An Update on Pharmacological Small-Molecule Inhibitors,” European Journal of Medicinal Chemistry 264 (2023): 116016.

[45] P. Atalay and B. Ozpolat, “PIM3 Kinase: A Promising Novel Target in Solid Cancers,” Cancers 16, no. 3 (2024): 535.

[46] L. Chen, P. Hou, Y. L. Zou, et al., “B7-H1 Agonists Suppress the PI3K/AKT/Mtor Pathway by Degrading p110gamma and Independently Induce Cell Death,” Cancer Letters 584 (2024): 216615.

[47] Y. Zhang, P. Lv, J. Ma, et al., “Antrodia Cinnamomea Exerts an Anti-Hepatoma Effect by Targeting PI3K/AKT-Mediated Cell Cycle Progression in Vitro and in Vivo,” Acta Pharmaceutica Sinica B 12, no. 2 (2022): 890–906.

[48] M. Ferrell, D. C. Guven, C. G. Gomez, et al., “Investigating the WNT and TGF-Beta Pathways Alterations and Tumor Mutant Burden in Young-Onset Colorectal Cancer,” Scientific Reports 14, no. 1 (2024): 17884.

[49] D. V. F. Tauriello, E. Sancho, and E. Batlle, “Overcoming TGFbeta-Mediated Immune Evasion in Cancer,” Nature Reviews Cancer 22, no. 1 (2022): 25–44.

[50] K. Sahlin, T. Baudeau, B. Cazaux, et al., “A Survey of Mapping Algorithms in the Long-Reads Era,” Genome Biology 24, no. 1 (2023): 133.

[51] T. Jiang, Y. Liu, Y. Jiang, et al., “Long-Read-Based Human Genomic Structural Variation Detection With cuteSV,” Genome Biology 21, no. 1 (2020): 189.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.